Multiple Myeloma Drug Blenrep Backed for Wider NHS Use

Why It Matters

By increasing access to a more effective second‑line option, the decision could improve survival outcomes for thousands of myeloma patients and boost GSK’s revenue potential in a fast‑growing oncology market.

Key Takeaways

• NICE expands Blenrep to 1,600 patients annually in England.
• Blenrep combined with Velcade and dexamethasone shows superior survival.
• Cancer Drugs Fund will temporarily cover Blenrep's cost under new guidance.
• GSK targets $4 billion peak sales, but 2025 forecast modest $22 million.
• Competition intensifies as alternative relapsed‑myeloma regimens seek approval.

Pulse Analysis

Multiple myeloma remains a challenging hematologic cancer, with relapse rates driving a constant search for more durable therapies. In England, the National Institute for Health and Care Excellence (NICE) plays a pivotal role in determining which treatments receive public reimbursement. By extending Blenrep’s indication to patients who have not yet been exposed to lenalidomide, NICE is aligning clinical evidence with patient need, effectively adding an estimated 1,600 new candidates to the therapy’s pool each year. This policy shift underscores the regulator’s willingness to act on emerging data rather than waiting for long‑term real‑world outcomes.

The clinical catalyst for the expanded use was the DREAMM‑7 trial, which showed the Blenrep‑Velcade‑dexamethasone regimen outperformed the Darzalex‑based standard in both progression‑free and overall survival. For patients, the benefit translates into an average remission extending beyond three years, a meaningful gain in quality of life and personal milestones. Financially, the Cancer Drugs Fund will shoulder the drug’s cost during the interim, mitigating budgetary pressure on NHS trusts and ensuring rapid patient access while the final guidance is polished.

For GSK, the decision is a strategic win. The company projects peak global sales of roughly $4 billion for Blenrep, yet 2025 forecasts remain modest at about $22 million, reflecting the early stage of market penetration. The drug now faces a crowded competitive landscape, with other manufacturers advancing novel anti‑CD38 and BCMA‑directed agents. Success will hinge on securing additional combination approvals—such as with pomalidomide—and demonstrating real‑world effectiveness that can sustain pricing and reimbursement in a cost‑conscious health system.